

Juan Manuel Sepúlveda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8879917/publications.pdf>

Version: 2024-02-01

73
papers

2,314
citations

430874

18
h-index

233421

45
g-index

77
all docs

77
docs citations

77
times ranked

3151
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	7.1	805
2	First-in-Human Dose Study of the Novel Transforming Growth Factor- β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560.	7.0	199
3	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1146-1156.	1.2	197
4	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	1.2	150
5	The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab. <i>Oncologist</i> , 2011, 16, 136-145.	3.7	118
6	Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. <i>Neuro-Oncology</i> , 2017, 19, 1522-1531.	1.2	88
7	Cardiac Safety of TGF- β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. <i>Cardiovascular Toxicology</i> , 2015, 15, 309-323.	2.7	74
8	A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). <i>Neuro-Oncology</i> , 2020, 22, 1851-1861.	1.2	64
9	Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1548-1558.	4.1	61
10	The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	46
11	Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. <i>Journal of Neuro-Oncology</i> , 2016, 127, 569-579.	2.9	40
12	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017, 18, 995.	4.1	32
13	Infigratinib in Patients with Recurrent Gliomas and <i>FGFR</i> Alterations: A Multicenter Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2270-2277.	7.0	30
14	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. <i>Nature Medicine</i> , 2022, 28, 752-765.	30.7	30
15	First-In-Human Phase I Study of a Next-Generation, Oral, TGF- β Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6666-6676.	7.0	27
16	A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 146, 79-89.	2.9	26
17	Pyrosequencing versus methylation-specific PCR for assessment of <i>MGMT</i> methylation in tumor and blood samples of glioblastoma patients. <i>Scientific Reports</i> , 2019, 9, 11125.	3.3	25
18	Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas. <i>PLoS Computational Biology</i> , 2019, 15, e1006778.	3.2	25

#	ARTICLE	IF	CITATIONS
19	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	1.2	25
20	Defining EGFR amplification status for clinical trial inclusion. <i>Neuro-Oncology</i> , 2019, 21, 1263-1272.	1.2	20
21	Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas. <i>Cancer Research</i> , 2021, 81, 2142-2156.	0.9	20
22	Dacomitinib: an investigational drug for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 823-829.	4.1	17
23	Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-12.	4.0	16
24	Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype. <i>Cancers</i> , 2020, 12, 3230.	3.7	16
25	Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3514-3514.	1.6	13
26	A clinically compatible drugâ€screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. <i>EMBO Molecular Medicine</i> , 2022, 14, e14552.	6.9	12
27	Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO). <i>Targeted Oncology</i> , 2020, 15, 613-622.	3.6	11
28	Morphologic Features on MR Imaging Classify Multifocal Glioblastomas in Different Prognostic Groups. <i>American Journal of Neuroradiology</i> , 2019, 40, 634-640.	2.4	10
29	Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer. <i>Ecancermedicalsecience</i> , 2019, 13, 891.	1.1	10
30	Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival. <i>Neurocirurgia</i> , 2019, 30, 11-18.	0.4	10
31	Impact of deparatuzumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. <i>European Journal of Cancer</i> , 2021, 147, 1-12.	2.8	10
32	Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. <i>Cancers</i> , 2022, 14, 2393.	3.7	8
33	The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2016, 18, 66.	4.0	6
34	Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumabâ€. <i>Neuro-Oncology Practice</i> , 2017, 4, 15-23.	1.6	6
35	Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2001-2001.	1.6	6
36	Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. <i>European Urology Oncology</i> , 2021, 4, 502-505.	5.4	5

#	ARTICLE	IF	CITATIONS
37	The oral transforming growth factor-beta (TGF- β) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.. Journal of Clinical Oncology, 2012, 30, 2042-2042.	1.6	5
38	A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma.. Journal of Clinical Oncology, 2015, 33, 2014-2014.	1.6	5
39	A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCulating Endothelial cells) Study (SOGUG-CEC-2011-01). European Urology Focus, 2017, 3, 430-436.	3.1	4
40	Analysis of response rate with anti-PD1/PDL1 antibodies in advanced solid tumors: A meta-analysis of randomized clinical trials (RCT).. Journal of Clinical Oncology, 2017, 35, e14576-e14576.	1.6	4
41	Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma. Neurology, 2016, 87, 114-115.	1.1	3
42	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. Neuro-Oncology, 2019, 21, vi12-vi12.	1.2	3
43	Cabazitaxel in patients with advanced CRPC after docetaxel failure: Results of expanded program access (EAP) in Spain: Safety and efficacy.. Journal of Clinical Oncology, 2012, 30, e15149-e15149.	1.6	3
44	RB-independent activity of Cdk4/6 in bladder cancer.. Journal of Clinical Oncology, 2016, 34, e16011-e16011.	1.6	3
45	The role of pharmacogenomics in metastatic renal cell carcinoma. Cancer and Metastasis Reviews, 2012, 31, 29-32.	5.9	2
46	Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. European Urology Focus, 2017, 3, 280-286.	3.1	2
47	Targeting EGFR in glioblastoma: Preclinical testing of dacomitinib.. Journal of Clinical Oncology, 2014, 32, e13015-e13015.	1.6	2
48	Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: A Spanish group for research in neurooncology (GEINO) trial.. Journal of Clinical Oncology, 2019, 37, 2038-2038.	1.6	2
49	Interim analysis of a phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETHIO21).. Journal of Clinical Oncology, 2019, 37, 2613-2613.	1.6	2
50	IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas. Neurotherapeutics, 2022, 19, 408-420.	4.4	2
51	Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study. Future Science OA, 2022, 8, .	1.9	2
52	ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX-M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE		

#	ARTICLE	IF	CITATIONS
55	Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.. Journal of Clinical Oncology, 2014, 32, e16074-e16074.	1.6	1
56	Efficacy of multikinase inhibitors (MKIs) in successive treatment lines of refractory advanced thyroid cancer patients (pts).. Journal of Clinical Oncology, 2016, 34, e17553-e17553.	1.6	1
57	GEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotinib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB): Results of the dose-escalation phase.. Journal of Clinical Oncology, 2018, 36, 2054-2054.	1.6	1
58	Tumor cell vanishing with radiological changes suggesting progression in IDH-mutated diffuse astrocytoma treated only with surgery. , 2018, 37, 217-220.		1
59	Prospective exploratory analysis of the association between genetic polymorphisms and sunitinib toxicity and efficacy in metastatic renal-cell carcinoma.. Journal of Clinical Oncology, 2012, 30, 4620-4620.	1.6	1
60	Clinical activity and cardiac tolerability of metronomic non-pegylated liposomal doxorubicin in heavily pre-treated patients with metastatic breast cancer: A single institution experience.. Journal of Clinical Oncology, 2015, 33, e11570-e11570.	1.6	1
61	CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, TPS4603-TPS4603.	1.6	1
62	ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL. Neuro-Oncology, 2018, 20, vi22-vi22.	1.2	0
63	Long-term outcomes of cisplatin-based chemotherapy in patients with stage II-III germ cell tumors: Center 30-year experience of a single center.. Journal of Clinical Oncology, 2013, 31, 338-338.	1.6	0
64	Genetic polymorphisms and sunitinib outcome in metastatic renal-cell carcinoma: A prospective observational study and validation.. Journal of Clinical Oncology, 2013, 31, 403-403.	1.6	0
65	Clinical value of PET/CT's SUV max at baseline, early follow-up, and end of treatment reevaluation as a prognostic factor in small cell lung cancer patients with extended disease.. Journal of Clinical Oncology, 2013, 31, e18558-e18558.	1.6	0
66	A multicenter randomized study comparing temozolomide (TMZ) versus TMZ-plus-bevacizumab (BEV) before standard treatment in unresectable glioblastoma (GBM) patients (p): The GENOM 009 study by the GEINO group.. Journal of Clinical Oncology, 2014, 32, 2028-2028.	1.6	0
67	The frequency and impact of ROS1 rearrangement on clinical outcomes in GBM.. Journal of Clinical Oncology, 2014, 32, 2093-2093.	1.6	0
68	Phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer for neurotoxicity characterization: An Oncosur Study Group study.. Journal of Clinical Oncology, 2015, 33, 1029-1029.	1.6	0
69	Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2016, 34, e16129-e16129.	1.6	0
70	Association of risk of febrile neutropenia (FN) with docetaxel in prostate cancer (PC) patients: A meta-analysis of published phase II-III trials.. Journal of Clinical Oncology, 2017, 35, e21683-e21683.	1.6	0
71	A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETH021).. Journal of Clinical Oncology, 2018, 36, TPS3123-TPS3123.	1.6	0
72	CTNI-51. ADJUVANT TROTABRESIB, A REVERSIBLE POTENT BROMODOMAIN AND EXTRATERMINAL INHIBITOR, PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: INTERIM RESULTS FROM A PHASE 1B DOSE-FINDING STUDY. Neuro-Oncology, 2021, 23, vi71-vi72.	1.2	0

#	ARTICLE	IF	CITATIONS
73	CTNI-16. TROTABRESIB (CC-90010, BMS-986378), A REVERSIBLE, POTENT ORAL BROMODOMAIN AND EXTRATERMINAL INHIBITOR (BETi) IN PATIENTS WITH HIGH-GRADE GLIOMAS: A PHASE 1 OPEN-LABEL "WINDOW OF OPPORTUNITY"™ STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi62-vi62.	1.2	0